RNTX
Rein Therapeutics, Inc.
Key Financials
Operating Income
$-50631000
↑ 22.2%
EPS (Diluted)
$-1.96
↑ 44.2%
Net Income
$-49871000
↑ 20.7%
Revenue
$0
NaN%
Total Liabilities
$7.2M
↓ 7.2%
Shareholders' Equity
$16.9M
↓ 68.9%
Cash & Equivalents
$3.2M
↓ 75.0%
Total Assets
$24.2M
↓ 61.2%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 10-Q | 5/15/2026 | View on SEC |
| 4 | 5/13/2026 | View on SEC |
| SCHEDULE 13G/A | 5/8/2026 | View on SEC |
| SCHEDULE 13G | 5/8/2026 | View on SEC |
| SCHEDULE 13G | 5/7/2026 | View on SEC |
| SCHEDULE 13G | 5/6/2026 | View on SEC |
| 8-K | 5/4/2026 | View on SEC |
| 424B5 | 5/4/2026 | View on SEC |
| EFFECT | 4/30/2026 | View on SEC |
| S-1 | 4/28/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | RNTX |
| Company Name | Rein Therapeutics, Inc. |
| CIK | 1420565 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| Phone | 7378021989 |